<DOC>
	<DOCNO>NCT02343835</DOCNO>
	<brief_summary>This protocol study impact Irreversible electroporation ( IRE ) immune response patient diagnose unresectable pancreatic cancer small 5.0 cm . It profile immune response IRE unresectable pancreatic cancer . The intra-tumoral systemic immune response IRE determine compare pre-ablated pancreatic cancer specimens historical control specimen .</brief_summary>
	<brief_title>Anti-Tumor Immunity Induced IRE Unresectable Pancreatic Cancer</brief_title>
	<detailed_description>Thirty patient histologically confirm locally advanced pancreatic adenocarcinoma ( ≤5.0cm ) undergo percutaneous irreversible electroporation tumor use CT ultrasound guidance . Blood drawn research IRE . Blood tissue sample use . After IRE , patient carefully monitor systemic immune response register . Follow-up consist frequent CT MRI scanning , well serum CA19.9 tumor marker quality life questionnaires overall survival ( OS ) . The investigator hypothesize IRE pancreas induce good symptom palliation without cause severe complication well perfect systemic immune response .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Radiologic confirmation unresectable pancreatic cancer least CT chest abdomen Screening must perform longer 2 week prior study inclusion Maximum tumor diameter ≤ 5 cm ; Histological cytological confirmation pancreatic adenocarcinoma ; Age ≥ 18 year ; ASAclassification 0 3 Life expectancy least 12 week ; Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day prior definite inclusion ; Hemoglobin ≥ 5.6 mmol/L ; Absolute neutrophil count ( ANC ) ≥ 1,500/mm3 ; Platelet count ≥ 100*109/l ; Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) ; ALT AST ≤ 2.5 x ULN ; Serum creatinine ≤ 1.5 x ULN calculate creatinine clearance ≥ 50 ml/min ; Prothrombin time INR &lt; 1.5 x ULN ; Activated partial thromboplastin time &lt; 1.25 x ULN ( therapeutic anticoagulation therapy allow treatment interrupt judge treat physician ) ; Written inform consent ; Resectable pancreatic adenocarcinoma discuss multidisciplinary hepatobiliary team ; Successful staging ( radio ) chemotherapy previous unresectable/borderline tumor resectable tumor ; History epilepsy ; History cardiac disease : Congestive heart failure &gt; NYHA class 2 ; Active Coronary Artery Disease ( define myocardial infarction within 6 month prior screen ) ; Cardiac arrhythmia require antiarrhythmic therapy pacemaker ( beta blocker antihypertensive regimen permit ) ; Uncontrolled hypertension . Blood pressure must ≤160/95 mmHg time screen stable antihypertensive regimen ; Compromised liver function ( e.g . sign portal hypertension , INR &gt; 1,5 without use anticoagulant , ascites ) ; Uncontrolled infection ( &gt; grade 2 NCICTC version 3.0 ) ; Pregnant . Women childbearing potential must negative pregnancy test perform within 7 day start treatment ; Immunotherapy ≤ 6 week prior procedure ; Chemotherapy ≤ 6 week prior procedure ; Radiotherapy ≤ 6 week prior procedure ; Concomitant use anticonvulsive antiarrhythmic drug ( beta blocker use antihypertensive ) ; Allergy contrast medium ; Any implant stimulation device ; Any implant metal stent/device within area ablation remove ; Any condition unstable could jeopardize safety subject compliance study ; Of note , patient contraindication MRI exclude participation : case radiologic followup consist CTscanning accord protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>